As of May 2012 websites are required by law to gain your consent before applying cookies. We use cookies to improve your browsing experience. Parts of the website may not work as expected without them. By closing this message, you are consenting to our use of cookies. Close Learn more


Hepatitis C


> Download your free sample > Contact us to find out more



This comprehensive coverage provides up-to-date opinions and forecasts based on extensive secondary research backed by a survey of 126 high prescribing specialists and detailed discussions with KOLs.  Learn how the disease is currently treated, the unmet needs and how new market entrants (branded and generics/biosimilars) will affect the market in the future.

The Datamonitor Healthcare difference



Total number of physicians interviewed

US Japan France Germany Italy Spain UK
33 16 15 15 16 15 16


Coverage summary

Reports included in package
  • Epidemiology
  • Marketed drugs profiles
  • Pipeline drugs profiles
  • Treatment (physician insights)
  • Patient-based drug forecasts
Countries evaluated US, Japan, France, Germany, Italy, Spain, UK
Patient-based drug forecast period 2012–22
Patient subpopulations forecasted
  • Genotype 1
  • Genotype 2/3
Drugs profiled
  • Incivek
  • Victrelis
  • Simeprevir
  • ABT-450/r, ABT-267
  • Asunaprevir
  • Daclatasvir
  • Faldaprevir
  • Peginterferon-lambda-1a
  • Sofosbuvir
  • Vaniprevir



Key Findings

Traditional interferon-based therapies suffer from poor tolerability profiles, extensive treatment durations, and large drops in efficacy in previous non-responders. Several big pharma companies (those with annual revenues in excess of $10bn) including AbbVie, Johnson & Johnson, and Bristol-Myers Squibb will address these unmet needs by developing interferon-free regimens with greatly improved clinical profiles and treatment durations as short as 12 weeks.

> Download your free sample > Contact us to find out more

Datamonitor Healthcare is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726